Life Sciences Greenhouse of Pennsylvania

LSGPA partners with a range of institutions, including local research universities, colleges, medical centers, economic development agencies and companies both small and large, to identify needs and opportunities. LSGPA then works to help transfer technologies, to develop new companies, to provide support for existing companies (particularly those seeking to expand or relocate), and to ensure that the infrastructure necessary to support a thriving life sciences industry keeps pace with development.

Melvin Billingsley

President, CEO and Director

Steve Carpenter

Vice President of Venture Operations

Henry C. Foley

Director

Ron Thiboutot

SVP

Ronald P. Thiboutot

EVP

17 past transactions

Micro Interventional Devices, Inc. is a medical device company focused on developing innovative technologies for percutaneous and minimally invasive structural heart repair procedures. Founded in 2010 and based in Newtown, Pennsylvania, the company specializes in products such as Permaseal, a device for transapical access and closure during catheter-based interventions; Minimally Invasive Annuloplasty for tricuspid and mitral valve repair; and Endovalve, a system for percutaneous mitral valve replacement. Additionally, the company offers Permavalve, a percutaneous mitral valve with active fixation. Micro Interventional Devices aims to shift traditional open surgical methods to less invasive transcatheter procedures, enhancing patient outcomes and procedural efficiency.

MacuLogix

Series D in 2019
MacuLogix, Inc. specializes in the diagnosis, monitoring, and treatment of age-related macular degeneration (AMD), a leading cause of blindness. The company offers the AdaptDx, a fully automated dark adaptometer designed to aid eye care professionals in detecting and tracking AMD at its earliest stages, potentially up to three years before it becomes visible. This early detection capability allows for timely intervention, which can help prevent vision loss. MacuLogix markets its products through distributors in the United States and internationally, as well as online, to ensure accessibility for healthcare providers. Founded in 2008 and based in Harrisburg, Pennsylvania, MacuLogix is committed to leveraging the science of dark adaptation to combat preventable blindness associated with AMD.

MacuLogix

Venture Round in 2017
MacuLogix, Inc. specializes in the diagnosis, monitoring, and treatment of age-related macular degeneration (AMD), a leading cause of blindness. The company offers the AdaptDx, a fully automated dark adaptometer designed to aid eye care professionals in detecting and tracking AMD at its earliest stages, potentially up to three years before it becomes visible. This early detection capability allows for timely intervention, which can help prevent vision loss. MacuLogix markets its products through distributors in the United States and internationally, as well as online, to ensure accessibility for healthcare providers. Founded in 2008 and based in Harrisburg, Pennsylvania, MacuLogix is committed to leveraging the science of dark adaptation to combat preventable blindness associated with AMD.

INDIGO Biosciences

Series B in 2016
INDIGO Biosciences, Inc. was founded in 2005 in State College, PA. It remains a privately held biosciences company offering products and services focused on nuclear receptors, which comprise a major class of therapeutic drug targets. The Company's two founders, Dr. Jack Vanden Heuvel and Dr. Blake Peterson, leveraged their collective expertise's in nuclear receptor biology, toxicology, medicinal chemistry and molecular biology to establish the core platform technology of The Company.

MacuLogix

Series C in 2015
MacuLogix, Inc. specializes in the diagnosis, monitoring, and treatment of age-related macular degeneration (AMD), a leading cause of blindness. The company offers the AdaptDx, a fully automated dark adaptometer designed to aid eye care professionals in detecting and tracking AMD at its earliest stages, potentially up to three years before it becomes visible. This early detection capability allows for timely intervention, which can help prevent vision loss. MacuLogix markets its products through distributors in the United States and internationally, as well as online, to ensure accessibility for healthcare providers. Founded in 2008 and based in Harrisburg, Pennsylvania, MacuLogix is committed to leveraging the science of dark adaptation to combat preventable blindness associated with AMD.

MacuLogix

Series A in 2013
MacuLogix, Inc. specializes in the diagnosis, monitoring, and treatment of age-related macular degeneration (AMD), a leading cause of blindness. The company offers the AdaptDx, a fully automated dark adaptometer designed to aid eye care professionals in detecting and tracking AMD at its earliest stages, potentially up to three years before it becomes visible. This early detection capability allows for timely intervention, which can help prevent vision loss. MacuLogix markets its products through distributors in the United States and internationally, as well as online, to ensure accessibility for healthcare providers. Founded in 2008 and based in Harrisburg, Pennsylvania, MacuLogix is committed to leveraging the science of dark adaptation to combat preventable blindness associated with AMD.

Micro Interventional Devices

Pre Seed Round in 2012
Micro Interventional Devices, Inc. is a medical device company focused on developing innovative technologies for percutaneous and minimally invasive structural heart repair procedures. Founded in 2010 and based in Newtown, Pennsylvania, the company specializes in products such as Permaseal, a device for transapical access and closure during catheter-based interventions; Minimally Invasive Annuloplasty for tricuspid and mitral valve repair; and Endovalve, a system for percutaneous mitral valve replacement. Additionally, the company offers Permavalve, a percutaneous mitral valve with active fixation. Micro Interventional Devices aims to shift traditional open surgical methods to less invasive transcatheter procedures, enhancing patient outcomes and procedural efficiency.

Immunomic Therapeutics

Venture Round in 2010
Immunomic Therapeutics, Inc., a clinical-stage biotechnology company, conducts studies nucleic acid immunotherapy platforms for immunotherapy for the treatment of cancer, allergies, and animal health. The company provides UNiversal Intracellular Targeted Expression (UNITE) platform for cancer immunotherapy, allergy, and infectious diseases. It offers LAMP-Vax platform for DNA vaccine for antigen presentation and enhances immune system responses to vaccination. Immunomic Therapeutics, Inc. was founded in 2005 and is based in Rockville, Maryland with an additional office in South Korea.

INDIGO Biosciences

Seed Round in 2008
INDIGO Biosciences, Inc. was founded in 2005 in State College, PA. It remains a privately held biosciences company offering products and services focused on nuclear receptors, which comprise a major class of therapeutic drug targets. The Company's two founders, Dr. Jack Vanden Heuvel and Dr. Blake Peterson, leveraged their collective expertise's in nuclear receptor biology, toxicology, medicinal chemistry and molecular biology to establish the core platform technology of The Company.

NanoHorizons

Series B in 2008
NanoHorizons Inc. specializes in the invention, design, and manufacture of nanoscale silver additives that deliver antimicrobial protection across a range of consumer, commercial, and industrial applications. Its key product, SmartSilver, is an antimicrobial additive effective in controlling bacteria and is suitable for use in natural and synthetic fibers, fabrics, coatings, foams, and polymer products. The company serves diverse sectors, including apparel, healthcare, and coatings and plastics, catering to both domestic and international markets. Founded in 2002, NanoHorizons is headquartered in Bellefonte, Pennsylvania, and focuses on combining science and technology to create safe and effective nanoparticle solutions.

Novasentis

Series A in 2008
Novasentis (formerly Strategic Polymer Sciences, Inc.), created the world’s first electro-mechanical polymer (EMP), the thinnest and most flexible haptic actuator and sensor technology today, used to develop mobile and wearable products that come alive with movement and sound. By bridging consumer electronics and sensory interaction, Novasentis enables 4D spatial tactile experiences and next-generation mobile product designs. Novasentis is privately funded. The company is based in San Francisco Bay Area and has offices in Pennsylvania, Korea, and Tokyo. More information on Novasentis is online at www.novasentis.com

INRange Systems

Grant in 2006
INRange Systems, Inc. specializes in developing medication delivery systems that enhance medication management for healthcare providers. The company offers EMMA, a remote medication management system designed to control the dispensing of individual medication doses, which is remotely programmed by pharmacists through a web-based platform. Additionally, INRange Systems provides E-Kit, which facilitates individual unit dose control for narcotics and inventory management for non-narcotics, alongside a Narcotics Control solution aimed at long-term care pharmacies for packaging and dispensing medications. The company serves a range of clients, including independent and assisted living facilities, skilled nursing facilities, managed care organizations, and pharmacies. Founded in 2002 and headquartered in Altoona, Pennsylvania, INRange Systems is committed to improving medication adherence and administration through its innovative solutions.

SoftGenetics

Pre Seed Round in 2006
SoftGenetics provides researchers and clinicians with software analysis tools for genetic analysis. It offers Mutation Surveyor, which provides discovery of DNA variants from sanger sequencing traces; NextGENe, a condensation tool, which polishes and lengthens short sequence reads into fragment sizes; GeneMarker, a genotyping software with application oriented defaults that reduces analysis set-up time; GeneMarker human identity software for various forensic profiling applications; JelMarker, an image reading software; and CGH Explorer for identifying genomic regions with copy number alterations. The company also provides analysis services.
Chaperone Tecnologies is developing antimicrobial products, based on a novel and proprietary mechanism of action, for difficult-to-treat and drug-resistant organisms across a broad range of infectious diseases.

INRange Systems

Grant in 2006
INRange Systems, Inc. specializes in developing medication delivery systems that enhance medication management for healthcare providers. The company offers EMMA, a remote medication management system designed to control the dispensing of individual medication doses, which is remotely programmed by pharmacists through a web-based platform. Additionally, INRange Systems provides E-Kit, which facilitates individual unit dose control for narcotics and inventory management for non-narcotics, alongside a Narcotics Control solution aimed at long-term care pharmacies for packaging and dispensing medications. The company serves a range of clients, including independent and assisted living facilities, skilled nursing facilities, managed care organizations, and pharmacies. Founded in 2002 and headquartered in Altoona, Pennsylvania, INRange Systems is committed to improving medication adherence and administration through its innovative solutions.

Xbio Systems

Venture Round in 2006
Xbio Systems provides integrated software solutions for the global Life Sciences sector. Their solutions have been designed to reduce business risk, improve governance and regulatory compliance, increase user acceptance, maximize operational control and reduce the cost of IT.